Dabigo 75 mg
| SKU | 2637 |
|---|---|
| Generic For | Pradaxa |
| Generic Name | Dabigatran Etexilate |
| Manufacturer | MSN Laboratories Ltd |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Capsule/s | US$ 0.62 | US$ 18.60 | |||
|
|||||
| 60 Capsule/s | US$ 0.56 | US$ 33.4810%US$ 37.20 | |||
|
|||||
| 90 Capsule/s | US$ 0.53 | US$ 47.4315%US$ 55.80 | |||
|
|||||
Dabigo 75mg
Dabigo 75mg is used in the following conditions:
- Prevention of blood clots in the veins of adult patients who have undergone hip or knee replacement therapy
- Reduction in the risk of stroke and blood clots in adult patients with irregular heart rhythm
- Treatment and prevention of blood clots in the body's deep veins and blockage of a pulmonary artery in your lungs (clinically termed as pulmonary embolism)
Doctors may prescribe it to treat blood clots and prevent them in paediatric patients from 0 to 18 years of age. For age-appropriate doses form, please contact your doctor.
How to use Dabigo 75 mg?
Dabigo 75t mg can be used in adults and paediatric patients aged eight years or older to swallow the capsule. Consult your doctor for dose recommendations and duration of therapy for primary prevention of blood clots in orthopaedic surgery.
If you miss a dose, it is suggested to continue with the remaining daily doses of the anticoagulant medicine at the same of the next day. Do not double up doses to make up for missed individual doses. Treatment should not be discontinued without doctor's advice. You should contact your doctor if you develop gastrointestinal symptoms such as dyspepsia. Treatment with Dabigo 75 mg in patients with renal impairment is contraindicated. A dose reduction is recommended for the elderly and patients with moderate renal insufficiency.
What precautions should be taken?
There is no relevant use of Dabigo capsules in the paediatric populations to indicate primary prevention of blood clots in individuals who have undergone hip or knee replacement surgery. Contact your doctor for more information. People with active bleeding and severe renal impairment should not use Dabigatran formulations. The anticoagulant drug should be used cautiously in conditions with an increased risk of bleeding or concomitant use of other products affecting blood clots.
Women of childbearing potential should avoid pregnancy during anticoagulant therapy. There is no limited evidence that shows the safety and effectiveness of Dabigo 75 mg in pregnant women. Dabigatran capsules should not be used during pregnancy unless necessary. No clinical data shows the blood thinner effect on infants during breastfeeding. But it is a wise decision to discontinue treatment. Talk to your doctor for more information.
What are the side effects of Dabigo 75 mg?
The most reported side effect is bleeding. Although rare, major severe bleeding may occur, leading to fatal outcomes.
Login
Sign Up
Login
Sign Up